ABUSE DETERRENT SOFT CHEWABLE DRUG FORMULATIONS
    6.
    发明申请
    ABUSE DETERRENT SOFT CHEWABLE DRUG FORMULATIONS 审中-公开
    滥用柔软咀嚼药物配方

    公开(公告)号:WO2017151571A1

    公开(公告)日:2017-09-08

    申请号:PCT/US2017/019869

    申请日:2017-02-28

    IPC分类号: A61K9/20 A61K31/485

    摘要: The present disclosure relates to oral, abuse deterrent, edible soft chewable dosage forms for delivery of drugs that are susceptible to abuse to a human or animal subject. The dosage forms are provided as chewable tablets manufactured using a compression (tablet) press. The edible soft chew dosage forms can be administered to subjects that are unable to swallow conventional tablets or capsules whole. One or more abuse deterrent measures in the dosage forms prevent the conversion of the dosage form into a residue or extract suitable for non-oral administration, such as intranasal or intravenous abuse. The present disclosure also relates to processes of preparing the dosage form. Such soft chew dosage forms have hardness less than 2 kilopond, preferably less than 1 kilopond, more preferably no measurable hardness when measured with tablet hardness tester and friability less than 1%, preferably less than 0.5 %, more preferably less than 0.1% for 100 rotations (per USP); 200 rotations or 300 rotations.

    摘要翻译: 本公开涉及用于将易于滥用的药物递送至人类或动物受试者的口服,滥用威慑,可食用软咀嚼剂型。 提供的剂型是作为使用压片机(压片机)制造的咀嚼片。 可食用的软咀嚼剂型可以给予不能吞服常规片剂或胶囊整体的受试者。 剂型中的一种或多种滥用威慑措施防止剂型转化为适合非口服给药的残留物或提取物,例如鼻内或静脉内滥用。 本公开还涉及制备该剂型的方法。 这样的软咀嚼剂型具有小于2千克的硬度,优选小于1千克的硬度,更优选当用片剂硬度测试仪测量时不具有可测量的硬度,并且脆碎度小于1%,优选小于0.5%,更优选小于0.1% 轮换(每USP); 200转或300转。

    ORAL DOSAGE PRODUCTS AND PROCESSES
    7.
    发明申请
    ORAL DOSAGE PRODUCTS AND PROCESSES 审中-公开
    口服剂量产品和工艺

    公开(公告)号:WO2017134418A1

    公开(公告)日:2017-08-10

    申请号:PCT/GB2017/050178

    申请日:2017-01-25

    申请人: UCL BUSINESS PLC

    摘要: A process for producing a solid pharmaceutical oral dosage formulation comprising (i) hot melt extrusion of a mixture comprising: (a) at least one drug, (b) at least one polymer, (c) at least one lubricant, and (d) optionally at least one plasticizer; to provide a pharmaceutical filament, and (ii) fused-deposition modelling 3-dimensional printing from the said pharmaceutical filament.

    摘要翻译: (i)热熔挤出混合物,所述混合物包含:(a)至少一种药物,(b)至少一种聚合物,(c)在 至少一种润滑剂,和(d)任选的至少一种增塑剂; 以提供药物长丝,和(ii)由所述药物长丝进行熔融沉积模拟三维印刷。

    NUTRACEUTICAL CONFECTIONARY COMPOSITION CONTAINING CAFFEINE AND L-THEANINE
    9.
    发明申请
    NUTRACEUTICAL CONFECTIONARY COMPOSITION CONTAINING CAFFEINE AND L-THEANINE 审中-公开
    含咖啡因和L-茶氨酸的营养组合物

    公开(公告)号:WO2017105564A1

    公开(公告)日:2017-06-22

    申请号:PCT/US2016/050822

    申请日:2016-09-08

    申请人: NEUROGUM, LLC

    摘要: In general, certain embodiments of the present disclosure provide compositions or mechanisms for oral administration of caffeine via a functional nutraceutical confectionary composition. According to various embodiments, a nutraceutical confectionary composition is provided with a ratio of caffeine to L-theanine ranging from about 1:1 to about 1:2. In some embodiments, the ratio of caffeine to L-theanine is about 2:3. In various embodiments, the nutraceutical confectionary composition may provide caffeine in a range from about 5 mg to about 100 mg per serving. L-theanine may be provided in a range from about 5 mg to about 200 mg per serving. In some embodiments, caffeine may comprise about 0.8% to 10% by weight of the composition; and L-theanine may comprise about 1.2% to 20% by weight of the composition. In certain embodiments, the nutraceutical confectionary composition may comprise a chewing gum.

    摘要翻译: 一般而言,本公开的某些实施方案提供了用于经由功能性营养保健品糖果组合物口服咖啡因的组合物或机制。 根据各种实施方案,提供了营养保健品糖食组合物,咖啡因与L-茶氨酸的比率在约1:1至约1:2的范围内。 在一些实施方案中,咖啡因与L-茶氨酸的比例为约2:3。 在各种实施方案中,营养食品糖果组合物可以提供每份约5mg至约100mg范围内的咖啡因。 L-茶氨酸可以以每份约5mg至约200mg的范围提供。 在一些实施方案中,咖啡因可占组合物的约0.8重量%至10重量% 并且L-茶氨酸可占组合物重量的约1.2%至20%。 在某些实施方案中,营养保健品糖果组合物可以包含口香糖。

    ABUSE DETERRENT PHARMACEUTICAL DOSAGE FORMS
    10.
    发明申请
    ABUSE DETERRENT PHARMACEUTICAL DOSAGE FORMS 审中-公开
    滥用药物剂量形式

    公开(公告)号:WO2017103111A1

    公开(公告)日:2017-06-22

    申请号:PCT/EP2016/081434

    申请日:2016-12-16

    IPC分类号: A61K9/20 A61K31/00

    摘要: The present invention relates to solid oral pharmaceutical dosage forms that provide extended release of active ingredients and have abuse deterrent properties and the methods of making the same. More particularly, the present invention relates to solid oral extended release abuse deterrent dosage forms comprising at least one polycaprolactone (PCL) and at least one gelling agent.

    摘要翻译: 本发明涉及提供活性成分的延长释放并具有滥用威慑性质的固体口服药物剂型及其制备方法。 更具体地说,本发明涉及包含至少一种聚己酸内酯(PCL)和至少一种胶凝剂的固体口服缓释剂滥用威慑剂型。